Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. Its key products include NXP800, a small molecule targeting ARID1a-mutated ovarian cancer and cholangiocarcinoma, and NXP900, a kinase inhibitor for solid tumors. The company aims to address unmet medical needs in oncology through innovative precision medicines, licensing, and strategic collaborations.
This description was generated via AI from an annual report. Updated about 1 year ago.